Support Intelligent, In-Depth, Trustworthy Journalism.
Leave your feedback
As the U.S. commits to vaccine distribution, Indonesia has recorded more than 4 million COVID cases. More than 140,000 people have died. Initially, Indonesia turned to China for vaccine aid. But Nick Schifrin explores how the U.S. and its allies are trying to achieve vaccine inroads in China’s backyard.
Judy Woodruff :
And we now take a different look at just how critical these vaccines can be.
Indonesia has recorded more than four million COVID cases. And the virus has killed more than 140,000 people there.
Nick Schifrin explores how the U.S. and its allies are trying to achieve vaccine inroads in China's backyard.
In Indonesia's newly dug COVID cemeteries, the grievers are barely old enough to wear a mask, row after row, column upon column, from the air, all symmetrical, as if preplanned.
But, on the ground, these graves were dug so quickly, the names are written in pen. The flowers and the heartache, are fresh. At the pandemic's peak this summer, grave diggers in head-to-toe PPE buried more than 200 bodies here a day. Across the country, the daily death toll was 3,000.
At first, the medical savior was China. Indonesia was the first country to approve Sinovac outside of China. China sent Indonesia its first Sinovac shipment in December 2020. In January, President Joko Widodo received the vaccine on live TV.
It's a pattern repeated worldwide. China exported nearly one billion Sinovac doses to more than 100 countries. It's created Sinovac plants in 15 countries. Indonesia has bought 125 million doses. But then health care workers started getting sick and dying.
Dr. Vera Irawany, ICU Doctor:
The cases made us feel overwhelmed. We feel like we want to scream. It's very exhausting because we are still racing. It's still a marathon.
Dr. Vera Irawany is an ICU doctor in Jakarta. She's seen firsthand Indonesia's strained health care system. Between January and June, more than 350 health care workers caught COVID. Dozens died. The majority of them had received Sinovac.
Dr. Vera Irawany (through translator):
Many patients came to us with critical conditions, even though they have been vaccinated. We were surprised because, even though these people were vaccinated, the results were still bad.
A University of Hong Kong study published last July found the Pfizer vaccine produced 10 times the level of antibodies as Sinovac. Another study shows Sinovac's efficacy rate is only 50 percent.
Tedros Adhanom Ghebreyesus, WHO Director General:
I'm happy to announce that the Sinovac-CoronaVac vaccine has been given WHO emergency use listing.
But even though China never released efficiency data, in April, the World Health Organization approved emergency use for Sinovac in a vaccine distribution program know as COVAX.
Dr. Chris Beyrer, Johns Hopkins University:
I would say that, at this point, putting forward, donating or contributing Sinovac to COVAX is no longer supported by the scientific evidence.
Chris Beyrer is an epidemiologist at Johns Hopkins university. He says the Pfizer and Moderna mRNA vaccines are new technology, while Sinovac uses traditional technology that uses an inactive SARS-CoV-2 virus. Scientists say the Chinese company over-inactivated the virus, decreasing its efficacy.
Dr. Chris Beyrer:
It's a very old-school technology, and it turns out that it just doesn't generate the same level of immune responses, but particularly as the coronavirus as changed and evolved over time with these new variants of concern.
In April, China's top disease control official admitted Chinese vaccines — quote — "don't have high protection rates."
But earlier this month, Chinese officials claimed the vaccine was effective against Delta in preventing severe cases and death.
Zheng Zhongwei, Chinese National Health Commission (through translator):
The current vaccines remain effective against all variants of the virus.
Dr. Dicky Budiman is an epidemiologist at Griffith University in Australia and advised the Indonesian government.
Dr. Dicky Budiman, Griffith University:
Indonesia has 270 million population. Even the commitment from China is not even fit with half of our total population.
But, still, that's a very, very significant and very important step for Indonesia to start with their vaccination program.
Indeed, initially, Sinovac was Indonesia's only choice, and Indonesia's first trials showed the vaccine was 95 percent effective in preventing serious illness and death, although it dropped from April to June to 79 percent.
Dr. Nadia Tarmiz, Indonesia COVID-19 Vaccine Program:
Can you imagine if we don't we need to wait and then we don't have any protection? It will be very worse for Indonesia.
Dr. Nadia Tarmizi is the spokesperson for Indonesia's vaccine program.
Dr. Nadia Tarmizi:
We think, if we don't have any protection with the vaccine, or, for example, if we need to wait until mRNA vaccine available in our country, we will have been facing a problem worse than the condition. At least there is still protection.
President Joe Biden:
The United States will purchase a half-a-billion doses.
But Sinovac's lower efficacy created a diplomatic opening. In June, the U.S. donated 500 million doses to COVAX, including three million to Indonesia. Last month, Dr. Irawany received a Moderna booster. Others have received Pfizer.
We hope to get the best. If we talk about evidence, data, then the mRNA vaccines are what is the best for now and are proven to be effective.
But vaccine diplomacy remains a competition. Last month, on her first trip to Southeast Asia, Vice President Kamala Harris planned to announce the U.S. would donate one million vaccines to Vietnam.
But during a three-hour flight delay, China stepped in and announced it would donate two million of its own vaccines. And, today, most of Indonesia still only has access to Sinovac.
Whatever vaccine that'S available, it will give you protection. So, of course, Sinovac will be still available.
The vaccine competition continued this week. Yesterday, Chinese President Xi Jinping promised to export another one billion vaccine doses this year.
The donations come with no political strings attached.
Today, President Biden announced the U.S. would donate an additional 500 million vaccines across the world.
But global health experts say that's not enough. For Indonesia right now, only 16 percent of the population is fully vaccinated.
Until now, we have had a lot of wealthy countries, of course, pre-purchasing vaccines and hoarding vaccines, so that COVAX, even if it had the money, didn't have the ability to purchase the high-efficacy vaccines.
And so the gravediggers continue their work. Indonesia's cases are down from their peak, but in areas outside the main cities, scientists warn that the worst wave is imminent.
For the "PBS NewsHour," I'm Nick Schifrin.
Watch the Full Episode
Nick Schifrin is the foreign affairs and defense correspondent for PBS NewsHour, based in Washington, D.C. He leads NewsHour's foreign reporting and has created week-long, in-depth series for NewsHour from China, Russia, Ukraine, Nigeria, Egypt, Kenya, Cuba, Mexico, and the Baltics. The PBS NewsHour series "Inside Putin's Russia" won a 2018 Peabody Award and the National Press Club's Edwin M. Hood Award for Diplomatic Correspondence. In November 2020, Schifrin received the American Academy of Diplomacy’s Arthur Ross Media Award for Distinguished Reporting and Analysis of Foreign Affairs.
Layla Quran is a general assignment producer for PBS NewsHour. She was previously a foreign affairs reporter and producer.
Support Provided By:
Support PBS NewsHour:
Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.
Thank you. Please check your inbox to confirm.